NZ314866A - Intravascular implantable stent with a chelating coating that binds to a preselected radioisotope - Google Patents

Description

New Zealand No. international No. 314866 PCT/ TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION Priority dates: 19.07.1996; Complete Specification Filed: 21.05.1997 Classification:^) A61M36/04; A61M5/00 Publication date: 29 April 1999 Journal No.: 1439 NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION Title of Invention: Radiation therapy method and device Name, address and nationality of applicant(s) as in international application form: ADVANCED CARDIOVASCULAR SYSTEMS, INC., a Californian corporation of 3200 Lakeside Drive, Santa Clara, California 95062, United States of America NEW ZEALAND ! 2f MAY 1997 PATENTS ACT, 1953 i, _ ■ RECBVED No: Date: COMPLETE SPECIFICATION RADIATION THERAPY METHOD AND DEVICE We, ADVANCED CARDIOVASCULAR SYSTEMS, INC. a California corporation having a place of business at 3200 Lakeside Drive, Santa Clara, California 95052, United States of America, do hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: followed by page - la - - la - 314 8 6 6 RADIATION THERAPY METHOD AND DEVICE BACKGROUND OF THE INVENTION The present invention generally relates to the use of radiation therapy to treat a condition such as restenosis and, more particularly, pertains to the use of an implantable device to deliver a dose of radiation.

A variety of conditions have been found to be amenable to treatment by the local irradiation of tissue. In order to appropriately limit the amount of tissue that is irradiated, it sometimes is necessary to implant a small source of radiation and, in order to expose the tissue to a sufficient 10 dosage of radiation, it has been found advantageous to implant such device for an extended period of time.

Percutaneous transluminal coronary angioplasty (PTCA) is an established treatment for coronary artery disease. The procedure involves inserting a balloon catheter through the 15 vasculature to a position where atherosclerotic plaque has collected on the vessel wall. The plaque is compressed against the vessel wall by inflating the balloon located at the distal end of the catheter in order to increase the diameter of the vessel and thereby reduce the restriction to blood flow. After 20 sufficient expansion has been achieved, the balloon is deflated and removed, and the area of disruption begins to heal.

While this procedure is very widely used, one problem associated with PTCA is a condition known as restenosis. Restenosis is the development of further blockage in the 25 intravascular structure, following an otherwise successful angioplasty procedure. Restenosis is believed to be an exaggerated form qf the normal healing process of the stretched tissue. Restenosis is thought to be caused by fibrointimal proliferation of the stretched wall in which the injured cells 30 lining the vascular structure multiply and form fibrous tissue. Such growth at the vascular wall is an almost malignant phenomenon in which normal cells multiply at a high rate, thereby creating a new obstruction to flow through the vascular structure. It occurs in the range of approximately 15-50 35 percent of the PTCA cases and typically presents within the i" /; Q first six months following PTCA. Stents have been implanted in expanded vessels in an effort to maintain patency but do not appear to have much of an effect on the restenosis rate. In the event a stent has been implanted, the growth tends to occur 5 around its ends and through any openings in its walls.

Localized irradiation of the vessel from within the vessel has been found to be effective in reducing the incidence of restenosis. To date, such radiation has been delivered via a number of different vehicles, including by guide wire, 10 balloon, temporarily implantable wire or permanently-implantable stent. The delivery device either is partially or wholly formed of radioactive material or alternatively, is coated with a radioactive substance. Material giving off high levels of radiation may be introduced briefly into the body and 15 then removed. Alternatively, material giving off a relatively lower level of radiation and with an appropriately short half-life may be introduced temporarily or, in some instances, left in place.

A number of shortcomings or disadvantages are 20 associated with the prior art devices and techniques. With respect to temporarily implanted devices, implantation time is limited and therefore the radiation dose necessarily must be very high. At such high dosage rates, local radiation burns may be caused on one side of the vessel while the opposite side 25 may receive a suboptimum dose. Moreover, due to the tendency of restenosis to occur throughout a six month period, repeated irradiation procedures would be necessary in order to adequately address the vagaries of onset.

In the case of permanently implanted devices, a 30 compromise be madfe* between the shelf life of the device and its in-vivo efficacious lifetime. If materials with short half-lives are used, in order to reduce the long term exposure of the patient to radiation, then the shelf life of the device necessarily must be short and therefore is undesirable. If, on 35 the other hand, an isotope is used which will permit a substantial shelf life, i.e.. an isotope having.a long half-life, then the exposure of the patient to radiation will be ;314 86 6 ;long term and may be excessive. Moreover, in view of the fact that the development of restenosis typically occurs within the first six months, it has been recognized that it is desirable to limit irradiation to such a time frame. Of course, 5 attempting to substantially restrict the release of radiation from a permanently implantable device to such a limited period of time imposes further constraints on the shelf life of the device. ;Another disadvantage inherent in the heretofore known 10 delivery devices is related to the need to adequately protect from exposure to unreasonable radiation dosages all who handle the device, including the manufacturing, stocking, and shipping personnel, catheter laboratory personnel, and physicians. This requires the use of large and cumbersome containers that 15 further complicate handling and disposal concerns. Some of the radioisotopes being considered in the industry require ion implantation into the device or transmutation of the metal in the device. The complexity of such processes greatly increases the cost of the devices. ;20 A new approach is necessary that would overcome the shortcomings of the prior art. It would be desirable to provide a system by which a very predictable dosage of radiation can be delivered via a permanently implantable device. Moreover, it would be most desirable for such device 25 to be producible at minimal cost, to have a substantial shelf life and present a minimal risk of exposure to radiation. ;SUMMARY OF THE INVENTION ;The present invention overcomes the shortcomings of the techniques and devices heretofore employed to deliver a 30 dose of radiation to a vascular site. A method is provided for precisely controlling the dosage that is delivered to the patient, while concerns relating to shelf-life of the device are obviated. Moreover, the hazards with respect to the handling of radioactive devices are substantially mitigated. 35 Additionally, the present invention provides a method for ;31 4 8 6 ;-4- ;quickly and easilv rendering an implantable device radioactive. More particularly, an implantable device is prepared so as to readily adsorb a preselected amount of radioactive material and to form a sufficiently strong bond therewith so as to 5 substantially minimize any subsequent loss thereof upon contact with bodily fluids. The present invention further provides a stent or other implantable device which facilitates the practice of such method. ;These advantages generally are achieved by 10 maintaining separate the implantable hardware and the radioactive material until just prior to implantation. By loading a precisely known quantity of material with a known half-life onto the device and immediately proceeding with the implantation procedure, a very precise dose of radiation can be 15 delivered to the patient over a desired period of time. ;Particular embodiments of present invention provide a stent that facilitates the adsorption of a predictable amount of radioactive material thereon in the surgery room. More particularly, a stent is provided that is coated with a 20 chelating agent. A base material and, optionally, a spacer material first is coated onto the device, after which the chelator is applied. This approach obviates any shelf life concerns related to the stent itself and obviates the need for special handling of the stent prior to loading. The base 25 material is selected to both form a strong bond with the surface of the stent as well as with the spacer or chelator applied thereover. The spacer is selected to form a strong bond with the underlying base layer as well as with the chelator and serves to impart a degree of mobility to the 30 chelator or to increase the number of active sites. Finally, the chelator is selected to form a strong bond with the base layer or spacer layer therebelow and of course ultimately adsorb the radioactive isotope. Such combinations of coatings are fairly tenacious, are substantially unaffected by the 35 disinfection processes the stent is normally subjected to and have no effect on the shelf life of the stent. ;31 4 8 s ;-5- ;Just prior to implantation, the chelator-coated device is immersed in a solution containing the appropriate radioactive material to adsorb the radioisotope. The chelator-isotope combination can be chosen such that the loading is 5 quantitative with virtually no subsequent release of the radioactive material from the implanted stent. Knowing the activity of the material along with the half-life of the radioisotope renders precisely calculable the total dosage of radiation that will be delivered. Precautions relating to the 10 radiation must only be taken when handling the vial containing the radioactive material and when handling the stent during and after the loading step. ;These and other features and advantages of the present invention will become apparent from the following 15 detailed description of preferred embodiments which, taken in conjunction with the accompanying drawing, illustrate by way of example the principles of the invention. ;BRIEF DESCRIPTION OF THE DRAWINGS ;FIGURE 1 is a perspective view of a typical stent 20 having an open lattice structure and embodying features of the present invention. ;FIG. 2 is a cross-section of one wire strut of the stent of FIG. 1 depicting the various layers attached to the stent. ;25 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS ;Particular embodiments of the present invention provide a system for delivering a precise dose of radiation to a vascular site via an implantable device. The device for example may be used to prevent restenosis in a blood vessel 3 0 that had been subjected to an angioplastic procedure. ;The device of the present invention preferably takes the form of a permanently implantable stent 10. The stent 10 ;1 1 4 H fl r* w initially is provided in a collapsed state and positioned about an inflatable balloon on the distal end of a catheter. Upon maneuvering the balloon into place within the target blood vessel, the balloon is inflated, which causes the stent to 5 radially expand. Any of various mechanisms well known in the art may be incorporated in the stent in order to lock the stent into its expanded state. Subsequent deflation of the balloon and extraction of the catheter leaves the expanded stent in place to maintain the patency of the blood vessel. Further 10 details of expandable stents and a balloon catheter delivery system are found in U.S. Patent No. 5,569,295, which issued October 29, 19 96 to Advanced Cardiovascular Systems, Inc. on an application filed May 3, 1995.

A stent 10 is prepared in accordance with the present 15 invention to deliver a preselected dose of radiation. FIGS. 1 and 2 depict the stent 10 embodying features of the present invention. The exterior surface 12 of the stent 10 first is selectively coated with a base layer 14 that serves as a primer or foundation. The base material is selected for its ability 2 0 to adhere or bond to the surface of the stent while providing a surface to which the next layer readily bonds. An intermediate spacer layer 16 optionally is bonded to the base layer for the purpose of providing sufficient mobility to the chelating functionality that subsequently is applied thereto 25 and/or to increase the number of active sites available to the chelating moiety thereby serving as a chemical amplifier. The chelator 18 is attached covalently to either the spacer material 16 or directly to the base layer 14. The chelator is selected to form a strong bond with the underlying-material and 30 to have a strong alffinity for the particular radioisotope to be used. The top layer is applied just prior to use and comprises the radioisotope that is adsorbed by the chelator. The radioisotope is selected based on the type of radiation it emits and its half-life. 3 5 The stent may be constructed of metal or a polymer.

Stainless steel is the preferred material of construction. 314 8 The base layer may comprise gold or any organic coating that contains a nucleophile, or potential nucleophile. These sites potentially could be aliphatic or benzylic carbons alpha to an ester, ketone or nitrile (i.e.. aliphatic or 5 benzylic carbons in the alpha position of an ester, ketone or nitrile). Alternatively, they could be alcohols, amines, ureas or thiols. Possible base layers include polyurethane, poly (ethylene-vinyl alcohols), poly (vinyl alcohols), most hydrogels and polyarcylates.

The spacer layer preferably is attached to the base layer by nucleophilic substitution due to the degree of control afforded by such reaction. Alternatively, radical grafting processes may be employed. Possible spacer materials include oc, cj- mercaptoalkylamines, diisocyanates, diacid chlorides, 15 dialkylamines, a, oj- hydroxyalkylamines, dihydroxyalkanes (PEO) and dimercaptoalkanes.

The chelator is selected to form a covalent bond with the underlying layer, i.e.. either the spacer or the base, and for a very high binding affinity for the radioisotope. 20 Possible chelator functionalities include acetates (monocarboxylic acids), acetylacetone, benzoylacetone, citric acid, 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, ethylenediamine-N,N,N',N'-tetraacetic acid, and pyridine-2,6-dicarboxylic acid.

The radioisotope is selected based on the type of emission, its half-life and the strength of its bond to the chelator, which must be sufficient so as not to be displaced by ions present in the blood. The preferred isotope is a beta emitter, because gamma radiation penetrates too deeply into 30 tissue and the energy of alpha particles is insufficient. The half-life of the radioisotope should be between 24 hours and 2 months, preferably between 2-18 days. The shorter the half-life, the more problematic becomes the shipping and storage of the radioactive material, while the longer the half-life, the 35 more excessive becomes the delivered the dosage in view of the biological process currently understood to be involved in the processes of restenosis. 314 8 6 The most preferred combination of materials is a stainless steel stent, a gold base layer, alpha, omega mercaptoalkylamine as a spacer, N1-(2-hydroxethyl) -ethylenedramine - IS^N.N1 - triacetic acid as a chelator and Ir192 5 as the radioisotope.

In the practice of the invention, the stent first is prepared by applying the base layer, then optionally the spacer layer and finally the chelator. The coated stent subsequently is sterilized and processed along with the stent and associated 10 devices. The subsequent shelf life and handling constraints substantially are dictated by the base stent and catheter rather than by the coating.

The radioisotope, suspended in a solution contained in a vial, is handled separately according to the general 15 methods with which hospitals are acquainted. Just prior to implantation, the stent is immersed in the vial in order to allow the chelator to adsorb the radioisotope. The loaded stent subsequently is maneuvered into position within the patient and expanded to be permanently left in place. The 20 radiation emitted by stent gradually diminishes as a function of its half-life but is sufficient during the critical six month time frame to preclude or at least minimize the chance of restenosis. Radiation subsequently continues to subside to insignificant levels obviating the need to remove the device. 25 While a particular form of the invention has been illustrated and described, it also will be apparent to those skilled in the art that various modifications can be made without departing from the scope of the invention. More particularly, any type of implantable device may be prepared in 30 accordance with the invention and the method may be practiced to treat any type of condition that has been found to respond to the localized irradiation of tissue. Accordingly, it is not intended that the invention be limited except by the appended claims.

Claims (13)

WHAT WE CLAIM IS: i 4 b o 8

1. An intravascular medical device for providing radiation treatment, the medical device comprising: an implantable component; a chelating coating attached to a preselected surface of the implantable component, the chelating coating being selected to have a binding affinity for a preselected radioisotope.

2. The intravascular medical device of claim 1, wherein the implantable component comprises an expandable stent.

3. The Lv. C? avascular medical device of claim 1, further comprising a base layer attached to the preselected surface of the implantable component and disposed below the chelating coating.

4. The intravascular medical device of claim 3, further comprising a spacer layer bonded to the base layer and disposed below the chelating coating.

5. The intravascular medical device of claim 4, wherein the base layer comprises gold and the spacer layer comprises a,u mercapto-alkyamine.

6. The intravascular medical device of claim 1, further comprising a radioactive isotope adsorbable by the chelating coating. INTELLECTUAL PROPERTY OFFICE OF N.Z. 1t> MAR 1999 -10- o i 4b (j 6

7. The intravascular medical device of claim 6, wherein the radioactive isotope comprises a 3-emitter.

8. The intravascular medical device of claim 7, wherein the 3-emitter has a half-life of between 24 hours and 2 months.

9. The intravascular medical device of claim 8, wherein the (3-emitter has a half-life of between 2 and 18 days.

10. A method for rendering an intravascular medical device radioactive, the method comprising: providing an implantable component having preselected sections thereof coated with a chelator, the chelator being selected to have a bonding affinity for a preselected radioisotope; radioisotope solution for a period of time sufficient to allow the radioisotope to be adsorbed by the chelated preselected sections of the implantable component.

11. An intravascular medical device substantially as herein described with reference to the accompanying drawings.

12. An intravascular medical device according to any one of claims 1-9 substantially as herein described.

13. A method for rendering an intravascular medical device radioactive substantially as herein described. providing the radioisotope- in solution; immersing the implantable component in the INTELLECTUAL PROPERTY OFFICE OFN.Z. end of claims 1 6 MAR 1999 received